StageZero Life Sciences Ltd
30.7.2021 01:01:40 CEST | ACCESS Newswire | Press release
TORONTO, ON / ACCESSWIRE / July 29, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company"), a healthcare company working to reduce the risk of cancer and other chronic diseases through early detection and intervention, today provided an update on its planned acquisition of Health Clinics Limited. The two companies have made excellent progress on the development of the definitive agreement for the transaction and are close to conclusion. However due to the complexity the companies have agreed to extend the timeframe and exclusivity for its completion to August 14, 2021.
"We continue to make progress on what is a complex, international transaction that will ultimately enable more patients to benefit from our combined strengths," said Chairman and CEO James Howard-Tripp. "Our planned acquisition of Health Clinics Limited promises to be transformative for StageZero and will greatly expand our existing partnership, including the broader use of telehealth capabilities to reach millions of consumers and employers who want to keep themselves and their employees healthy and avert chronic disease."
About StageZero Life Sciences, Ltd.
StageZero Life Sciences is dedicated to the early detection of multiple diseases through whole blood tests. The Company's next-generation test, Aristotle®, is the first-ever multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. StageZero's full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups, and the Company operates a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, leveraging its specialty in polymerase chain reaction (PCR) testing for the early identification of cancer through blood, StageZero also provides both COVID PCR testing (swab and saliva) and blood test analysis (Antibody testing). For more information, please visit www.stagezerolifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Rebecca Greco
Investor Relations
Tel: 1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences Ltd
View source version on accesswire.com:
https://www.accesswire.com/657723/StageZero-Life-Sciences-Provides-Update-on-Planned-Acquisition-of-Health-Clinics-Limited
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Iggy Azalea Invests in Shift - The AI Company Behind the Fastest-Growing Platform in the $1.3 Trillion Creator Economy, Fanvue27.8.2026 14:00:00 CEST | Press release
The Grammy-nominated artist and entrepreneur has made a significant investment in SHIFT, whose AI infrastructure has propelled its flagship platform, Fanvue, from a $4m to $200m annualised run rate in just over 2 years. LONDON, UK / ACCESS Newswire / August 27, 2026 / Iggy Azalea, the four-time Grammy-nominated artist, entrepreneur, and active investor, has personally invested a substantial sum in Fanvue's parent company SHIFT - the AI infrastructure the platform runs on. As part of the investment deal, Azalea will also become the founding member of SHIFT's Creator Advisory Board. The move comes at a time when the world's biggest creators, athletes and music artists are increasingly looking to multi-million-dollar equity opportunities in the creator economy - recent examples include MrBeast and the Paul brothers, Jake and Logan. AI is transforming how people make money online. For two decades, the creator economy has run on a simple trade: creators build the audience, and advertisers r
ZAGENO and ORO Labs Partner to Connect Scientific Purchasing with Enterprise Procurement26.8.2026 14:35:00 CEST | Press release
Partnership combines ORO Labs' AI-native procurement orchestration platform with ZAGENO's scientific marketplace and supplier network to deliver a governed, end-to-end purchasing experience for life sciences R&D. BOSTON, MA / ACCESS Newswire / August 26, 2026 / ZAGENO, the scientific procurement platform connecting researchers with 75 million laboratory products from approximately 5,500 suppliers, today announced a strategic partnership with ORO Labs, the AI-native procurement orchestration platform. The partnership connects ORO Labs' enterprise intake, workflow, and approval capabilities with ZAGENO's scientific product discovery, marketplace, supplier network, and fulfillment infrastructure. Together, the companies enable a single governed journey from request and approval through product selection, ordering, and fulfillment. Scientific R&D procurement has specialized requirements. Researchers need fast, intuitive access to highly specific products, while procurement teams need polic
Eudia Accelerates Enterprise AI Transformation with Google Cloud's Gemini Enterprise for Legal25.8.2026 15:50:00 CEST | Press release
PALO ALTO, CA / ACCESS Newswire / August 25, 2026 / Eudia, the augmented intelligence platform for enterprise legal, contracting, and compliance, today announced a partnership with Google to launch new industry-specific AI capabilities on Google Cloud's Gemini Enterprise for Legal. Eudia's agent scales the legal, contracting, and compliance expertise of an organization's top operators to every team in the enterprise. Built on Google's Agent Development Kit and connected via MCP, Eudia combines a suite of specialized agents with digital twins of domain-scoped institutional knowledge, orchestrated with legal-specific reasoning and access to legal databases. Eudia enables Legal, Compliance, Procurement, and Revenue teams to draft and review contracts, analyze marketing assets for compliance, assess risk across thousands of executed contracts, and manage obligations across the entire company portfolio, giving large enterprises a faster path to trusted, governed legal AI. In practice, this
Envision Pharma Group Names Ryan Tubbs, Senior Vice President, Commercial Growth25.8.2026 15:00:00 CEST | Press release
New role unifies sales enablement, lead generation, and marketing under centralized leadership and expands oversight to customer success, supporting a consistent, connected client experience across Envision. FAIRFIELD, CT / ACCESS Newswire / August 25, 2026 / Envision Pharma Group (Envision) has appointed Ryan Tubbs as Senior Vice President, Commercial Growth. In this newly created role, Tubbs will lead the centralized Commercial Growth function spanning sales enablement, lead generation, marketing, and client success. He will also help shape Envision's commercial strategy and operating model to accelerate enterprise growth. Tubbs' remit also includes the Client Implementation and Client Experience teams. Connecting Envision's pre-sale and post-sale capabilities will create a more integrated commercial engine, making it easier for teams to bring the best of Envision to clients and for clients to realize value quickly. The timing is notable as Envision's iEnvision®, market access, and m
Polaris Renewable Energy Announces Renewal of Normal Course Issuer Bid25.8.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / August 25, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today announced that the Toronto Stock Exchange ("TSX") has accepted its notice of intention to renew its normal course issuer bid ("NCIB"). The Company's Board of Directors believes that an NCIB represents an appropriate and desirable use of its available free cash to increase shareholder value and is in the best interest of the Company and its shareholders. Pursuant to the notice, Polaris may purchase up to 2,021,205 of its common shares ("Shares"), representing approximately 10% of the public float of 20,212,059 Shares as at August 13, 2026, during the twelve month period commencing August 27, 2026 and ending August 26, 2027, provided that the board of directors of Polaris has initially limited the NCIB to repurchase up to 176,872 Shares. As at August 13, 2026, there were 20,895,285 Shares issued and outstanding. Under the NCIB, other than purchases made under block
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom